Cellectricon is a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease. We are a team of highly experienced neurobiologists, stem cell researchers and engineers, with a proven track record of developing innovative in-vitro assays of enhanced translational value. With our unique drug discovery platform, we provide valuable decision-making information obtained from complex cell-based disease models. We always aim for long-term partnerships with our Clients, based on mutual trust and commitment.
Sponsors & Exhibitors
Ncardia believes that stem cell technology will help to get better medicines to patients faster. Ncardia develops produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC-derived cardiac (Cor.4U®, Pluricytes®,vCor.4U® & FibroCor.4U®) and neural (CNS.4U®, Peri.4U® and Astro.4U®) cell types. In addition, the company delivers the CardioPlate™ product line of quality controlled ready-to-use assay plates. Ncardia delivers working assay solutions & extensive support.
a leader in in vivo
drug discovery whose capabilities include behavioral testing,
electrophysiology, EEG, histology, and microdialysis. Complementing its
extensive capabilities are a variety of mouse models, including transgenic
models, in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s
disease and psychosis/schizophrenia. PsychoGenics has also pioneered the
translation of rodent behavioral responses into robust, high-throughput, high
content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube® and PhenoCube® have led to
shared risk partnerships with companies such as Sunovion and Roche and has
resulted in the discovery of several novel compounds in clinical trials or
advanced preclinical development.
from Charles River is industry-proven in the successful development of novel
therapies, with over 320 patents and 74 preclinical drug candidates delivered
to our sponsors in the past 17 years. Backed by more than 650 scientists, our
comprehensive, integrated portfolio employs the latest technology and platforms
to provide chemistry, biology, and pharmacology services that support clients from
the earliest stages of hit identification all the way through to IND. Our
client-focused, collaborative approach creates true partnerships that
anticipate challenges, overcome obstacles, and move us forward together on the
journey of getting new drugs to market.